Insider · CIK 0001200637
Regan J Lauer
Files at IBRX (ImmunityBio, Inc.). First filing -, latest -.
In brief
Regan J Lauer files SEC Form 4 as officer at IBRX (ImmunityBio, Inc.). No open-market trade is on file; the transactions below are grants, exercises and other rows that carry no view on the price.
A track record needs three past buys with six months of prices behind them; Regan J Lauer has 0, so none is measured yet.
Signals
This insider’s open-market buys and sells, scored.
Transactions
Every row this insider has filed, 21 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Feb 22, 2026 | IBRX ImmunityBio, Inc. | MOption exercise Common Stock | +4,065 | $0.00 | $0 | 117,548 | Feb 24, 2026 |
| Feb 22, 2026 | IBRX ImmunityBio, Inc. | FTax withholding Common Stock | -1,673 | $8.70 | $15k | 115,875 | Feb 24, 2026 |
| Feb 22, 2026 | IBRX ImmunityBio, Inc. | MOption exercise Restricted Stock Unitsderivative | -4,065 | $0.00 | $0 | 4,065 | Feb 24, 2026 |
| Feb 10, 2026 | IBRX ImmunityBio, Inc. | MOption exercise Common Stock | +5,482 | $0.00 | $0 | 115,740 | Feb 12, 2026 |
| Feb 10, 2026 | IBRX ImmunityBio, Inc. | FTax withholding Common Stock | -2,257 | $6.93 | $16k | 113,483 | Feb 12, 2026 |
| Feb 10, 2026 | IBRX ImmunityBio, Inc. | MOption exercise Restricted Stock Unitsderivative | -5,482 | $0.00 | $0 | 10,965 | Feb 12, 2026 |
| Feb 22, 2025 | IBRX ImmunityBio, Inc. | MOption exercise Common Stock | +4,065 | $0.00 | $0 | 111,927 | Feb 25, 2025 |
| Feb 22, 2025 | IBRX ImmunityBio, Inc. | FTax withholding Common Stock | -1,669 | $3.42 | $5,708 | 110,258 | Feb 25, 2025 |
| Feb 22, 2025 | IBRX ImmunityBio, Inc. | MOption exercise Restricted Stock Unitsderivative | -4,065 | $0.00 | $0 | 8,130 | Feb 25, 2025 |
| Feb 10, 2025 | IBRX ImmunityBio, Inc. | AGrant or award Restricted Stock Unitsderivative | +16,447 | $0.00 | $0 | 16,447 | Feb 12, 2025 |
| Feb 10, 2025 | IBRX ImmunityBio, Inc. | AGrant or award Stock Option (right to buy)derivative | +56,250 | $0.00 | $0 | 56,250 | Feb 12, 2025 |
| Dec 15, 2024 | IBRX ImmunityBio, Inc. | MOption exercise Common Stock | +21,031 | $0.00 | $0 | 115,365 | Dec 16, 2024 |
| Dec 15, 2024 | IBRX ImmunityBio, Inc. | FTax withholding Common Stock | -7,503 | $2.87 | $22k | 107,862 | Dec 16, 2024 |
| Dec 15, 2024 | IBRX ImmunityBio, Inc. | MOption exercise Restricted Stock Unitsderivative | -21,031 | $0.00 | $0 | 0 | Dec 16, 2024 |
| Feb 22, 2024 | IBRX ImmunityBio, Inc. | AGrant or award Restricted Stock Unitsderivative | +12,195 | $0.00 | $0 | 12,195 | Feb 26, 2024 |
| Feb 22, 2024 | IBRX ImmunityBio, Inc. | AGrant or award Stock Option (right to buy)derivative | +42,439 | $0.00 | $0 | 42,439 | Feb 26, 2024 |
| Jan 31, 2024 | IBRX ImmunityBio, Inc. | MOption exercise Common Stock | +32,872 | $0.00 | $0 | 107,804 | Feb 2, 2024 |
| Jan 31, 2024 | IBRX ImmunityBio, Inc. | FTax withholding Common Stock | -13,470 | $3.36 | $45k | 94,334 | Feb 2, 2024 |
| Jan 31, 2024 | IBRX ImmunityBio, Inc. | MOption exercise Restricted Stock Unitsderivative | -32,872 | $0.00 | $0 | 0 | Feb 2, 2024 |
| Dec 15, 2023 | IBRX ImmunityBio, Inc. | MOption exercise Common Stock | +21,030 | $0.00 | $0 | 74,932 | Dec 19, 2023 |
| Dec 15, 2023 | IBRX ImmunityBio, Inc. | MOption exercise Restricted Stock Unitsderivative | -21,030 | $0.00 | $0 | 21,031 | Dec 19, 2023 |
Questions about Regan J Lauer
Answered from the filings on this page, as of the latest one.
Is Regan J Lauer buying or selling?
Regan J Lauer has no open-market buy or sell on SEC Form 4; the filings on record are grants, exercises and other transactions.
How did Regan J Lauer's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Regan J Lauer has 0.
Where does Regan J Lauer file Form 4?
Regan J Lauer has filed Form 4 at IBRX (ImmunityBio, Inc.) as Chief Accounting Officer. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.